STAINES-UPON-THAMES, United Kingdom, Nov. 9, 2017 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that the company once again received a perfect score of 100 percent on the 2018 Corporate Equality Index (CEI), a national benchmarking survey and report on corporate policies and practices related to lesbian, gay, bisexual, transgender and queer (LGBTQ) workplace equality, administered by the Human Rights Campaign (HRC) Foundation.
"On behalf of Mallinckrodt employees, we are honored to earn this recognition from the Human Rights Campaign Foundation," said Mallinckrodt President and Chief Executive Officer Mark Trudeau. "We believe diversity and inclusion are fundamental to our company's success and the communities in which we operate, helping us to better innovate and collaborate as a company focused on advancing life-improving therapies for the patients we serve."
Mallinckrodt joins the ranks of 609 major U.S. businesses which also earned top marks this year. The 2018 CEI rated 947 businesses in the report, which evaluates LGBTQ-related policies and practices including non-discrimination workplace protections, domestic partner benefits, transgender-inclusive health care benefits, competency programs and public engagement with the LGBTQ community. Mallinckrodt's efforts in satisfying all of the CEI's criteria resulted in a 100 percent ranking and the designation as a Best Place to Work for LGBTQ Equality.
The HRC Foundation is the educational arm of America's largest civil rights organization working to achieve equality for lesbian, gay, bisexual, transgender and queer people. HRC envisions a world where LGBTQ people are embraced as full members of society at home, at work and in every community. For more information on the 2018 Corporate Equality Index, or to download a free copy of the report, visit www.hrc.org/cei.
Mallinckrodt's Inclusion & Diversity Council also recently earned honors as second best among top U.S. employee resource groups (ERGs), business resource groups (BRGs) and diversity councils. The company was recognized among more than 1,330 entrants at the 9th Annual ERG & Council Honors Award™ celebration in October. This premiere annual national award honors and celebrates outstanding contributions and achievements of resource groups and councils.
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
Senior Communications Manager
Chief Public Affairs Officer
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
Daniel J. Speciale, CPA
Director, Investor Relations
Vice-President, Government Affairs
SOURCE Mallinckrodt plc